For Healthcare Professionals

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

clipboard-pencil

About the study

The primary objectives of this study are: - To investigate the safety and tolerability, and to define the recommended Phase 2 dose and schedule (RP2DS) for magrolimab in combination with rituximab and for magrolimab in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx). - To evaluate the efficacy of magrolimab in combination with rituximab in participants with indolent lymphoma and diffuse large B-cell lymphoma (DLBCL) and to evaluate the efficacy of magrolimab in combination with R-GemOx in aspartate aminotransferase (ASCT) ineligible DLBCL participants.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Phase 1b only: B-cell non-Hodgkin's lymphoma (NHL), relapsed or refractory to standard approved therapies
  2. DLBCL Phase 2 cohort: De novo or transformed diffuse large B-cell lymphoma (DLBCL) expressing CD 20, relapsed or refractory to at least 2 prior lines treatment containing anti-CD20 therapy
  3. Indolent lymphoma Phase 2 cohort: Marginal zone or follicular lymphoma, relapsed or refractory to standard approved therapies
  4. DLBCL chemotherapy combination cohort: De novo or transformed diffuse large B-cell lymphoma (DLBCL), relapsed or refractory to 1-3 prior lines of treatment
  5. Adequate performance status and hematological, liver and kidney functions
  6. Willing to consent to 1 mandatory pre-treatment and 1 on-treatment tumor biopsy Key

EXCLUSION CRITERIA

  1. Active brain metastases
  2. Prior allogeneic hematopoietic cell transplantation
  3. Prior treatment with CD47 or signal regulatory protein alpha (SIRPα) targeting agents
  4. Second malignancy within the last 3 years
  5. Known active or chronic hepatitis B or C infection or HIV
  6. Pregnancy or active breastfeeding
  7. Prior chimeric antigen receptor (CAR-T) therapy Note: Other protocol defined Inclusion/Exclusion criteria may apply.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-833-445-3230 (GILEAD-0)Email iconEmail Study Center

Study’s details


Contition

Indolent Lymphoma,Lymphoma, Large B-Cell, Diffuse,Lymphoma, Non-Hodgkin,Non Hodgkin Lymphoma

Age

18+

Phase

Phase 1/Phase 2

Participants needed

178

Est. Completion Date

Aug 2026

Treatment type

Interventional


Sponsor

Gilead Sciences

ClinicalTrials.gov identifier

NCT02953509

Study number

5F9003

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.